eyeBrain Medical, Inc., a developer of a prescription lens that add a contoured prism to bring the eyes into alignment, has completed its Series D financing.
eyeBrain Medical, Inc. intends to use the proceeds of this financing to fuel the growth of its US commercialization strategy to reach 1,000 of the 23,000 existing optometric practices and 100,000 of their patients.
ROTH Capital Partners acted as financial advisor to the company.
About eyeBrain Medical, Inc.
eyeBrain Medical, Inc. is the innovator behind neurolenses®, the first prescription lenses that add a contoured prism to bring the eyes into alignment. Contoured prism has been shown in studies, to relieve the headaches, neck/shoulder pain and eyestrain that many people experience when using digital devices, reading or doing detail work. Patient satisfaction surveys show 93 percent of patients respond positively to their neurolenses. eyeBrain Medical is headquartered in Orange County, CA. For more information, please visit and
(Source: Company Press Release | 09/18/19)
About ROTH Capital Partners
ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and
their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading,
market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and
maintains offices throughout the U.S. For more information on ROTH, please visit
Date of Announcement:
The material, information and facts discussed in this announcement other than the information regarding ROTH Capital Partners, LLC
("ROTH") and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any
companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or
estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ
materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be
reproduced in any form without the express written permission of ROTH. Copyright 2019.